tiprankstipranks

Apellis price target lowered to $20 from $28 at Scotiabank

Scotiabank analyst Greg Harrison lowered the firm’s price target on Apellis (APLS) to $20 from $28 and keeps a Sector Perform rating on the shares. The company had a weak Q1, with Syfovre revenues in geographic atrophy missing expectations due to underfunding of retinal therapeutics co-pay assistance programs and inventory draw down, the analyst tells investors. The firm is lowering its price target on the stock to reflect its updated expectations for Syfovre sales.

Confident Investing Starts Here:

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & Disclosure

Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.

Report an Issue